Language selection

Search

Patent 2559634 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent Application: (11) CA 2559634
(54) English Title: PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF ARTHRITIS
(54) French Title: PREPARATIONS PHARMACEUTIQUES POUR LE TRAITEMENT DE L'ARTHRITE
Status: Deemed Abandoned and Beyond the Period of Reinstatement - Pending Response to Notice of Disregarded Communication
Bibliographic Data
(51) International Patent Classification (IPC):
  • A61K 33/34 (2006.01)
  • A61K 31/133 (2006.01)
  • A61K 31/197 (2006.01)
  • A61K 33/04 (2006.01)
  • A61K 33/32 (2006.01)
  • A61K 36/28 (2006.01)
  • A61K 36/324 (2006.01)
  • A61K 36/53 (2006.01)
  • A61K 36/76 (2006.01)
  • A61K 36/88 (2006.01)
  • A61K 36/90 (2006.01)
  • A61K 38/39 (2006.01)
  • A61K 38/48 (2006.01)
  • A61P 19/02 (2006.01)
(72) Inventors :
  • SHIPTON, ASHLEY (Canada)
  • HAUKENFRERS, REINHARDT (Canada)
(73) Owners :
  • KENT PEDERSEN
(71) Applicants :
  • KENT PEDERSEN (Canada)
(74) Agent: OYEN WIGGS GREEN & MUTALA LLP
(74) Associate agent:
(45) Issued:
(22) Filed Date: 2006-09-13
(41) Open to Public Inspection: 2008-03-13
Availability of licence: N/A
Dedicated to the Public: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): No

(30) Application Priority Data: None

Abstracts

English Abstract


The pharmaceutical composition for treating arthritis comprises
glucosamine or a salt thereof, plant materials or extracts, collagen,
pantothenic acid and minerals. The minerals may be copper, manganese
and selenium. The composition is made in a form for oral administration.
The combination of the mineral components with the glucosamine and the
plant materials produces a synergistic action in treating arthritis.


Claims

Note: Claims are shown in the official language in which they were submitted.


-6-
WHAT IS CLAIMED IS:
1. A pharmaceutical composition for treating arthritis,
comprising:
(a) glucosamine or a salt thereof;
(b) plant materials or extracts;
(c) collagen;
(d) pantothenic acid; and
(e) minerals.
2. A composition according to claim 1 wherein said minerals
comprise copper, manganese and selenium.
3. A composition according to claim 1 or 2 wherein said
glucosamine salt is glucosamine sulphate.
4. A composition according to any one of claims 1 - 3 wherein
said plant materials or extracts comprise boswellia extract, white
root bark, yucca root powder, devil's claw, sarsaparilla, feverfew
leaf powder and bromelain.
5. A composition according to any one of claims 1 - 4 wherein
said collagen is Type II collagen.
6. A composition according to any one of claims 1 - 5 wherein
said composition is in a form for oral administration.

-7-
7. A composition according to claim 6 wherein one dosage of
said composition for oral administration comprises at least 375 mg
of said glucosamine salt, at least 5 mg of pantothenic acid, at least
35 mg of copper, at least 750 mg of manganese and at least 13 mcg
of selenium.
8. A composition according to claim 6 or 7 wherein each of said
components is present in a medicinally-effective amount.
9. A composition according to any one of claims 1 - 7 wherein
said pantothenic acid, copper, manganese and selenium are present
at a level totaling at least 1% by weight of said pharmaceutical
composition.

Description

Note: Descriptions are shown in the official language in which they were submitted.


CA 02559634 2006-09-13
PHARMACEUTICAL PREPARATIONS
FOR THE TREATMENT OF ARTHRITIS
Field of the Invention
The invention pertains to compositions for treating arthritis in
humans and animals.
Background of the Invention
Medications for oral administration are known for the treatment of
arthritis which contain glucosamine, protein and various herbal materials
or extracts. It has been discovered by the present inventors that the
addition of certain compositions including minerals to such medications
can produce a medication having an enhanced effectiveness in treating
arthritis, and in particular in helping to form connective tissue in the
afflicted joints and to prevent further cartilage deterioration.
Summary of the Invention
The invention provides a pharmaceutical composition for treating
arthritis comprising glucosamine or a salt thereof, plant materials or
extracts, collagen, pantothenic acid, and minerals. The glucosamine salt is
preferably glucosamine sulphate. The minerals are preferably copper,
manganese and selenium. The composition can be made in a form for oral
administration, such as a capsule, and each capsule preferably contains at
least 375 mg of glucosamine sulphate, 5 mg of pantothenic acid, 350 mg of
copper, 750 mg of manganese and 13 mcg (micrograms) of selenium, in
addition to the other components. The combination in the composition of
the mineral components with the glucosamine and the plant materials
produces a synergistic action in treating the arthritis and the pain caused by
it.

CA 02559634 2006-09-13
-2-
These and other features of the invention will be apparent from the
following description of the preferred embodiments.
Description of the Preferred Embodiments
The pharmaceutical compositions of the invention are for oral
administration and comprise components which serve a number of
necessary functions in effectively treating arthritis. These functions
include relieving pain, relieving inflamation, rebuilding cartilage and
preventing cartilage deterioration. The compositions comprise
glucosamine or a salt thereof, plant materials, collagen, pantothenic acid
(Vitamin B5), and minerals, preferably copper, manganese and selenium.
Glucosamine is an amino acid derivative. It is used in the
composition to protect against deterioration of cartilage and contribute to
the building of heathy cartilage. It is preferably in the form of one of its
salts, such as glucosamine sulphate (which is preferred) or glucosamine
hydrochloride. One dose of the composition contains approximately 375
mg of glucosamine sulphate, or the equivalent amount of glucosamine in
another form.
The plant materials or extracts that are components of the
composition are preferably boswellia extract, white willow bark, yucca
root powder, devil's claw, sarsaparilla, feverfew leaf powder and
bromelain.
Boswellia extract acts as an anti-inflammatory agent. The preferred
form used in the composition is derived from Boswellia serrata and is
standardized to contain about 65% boswellic acid. One dosage of the
composition contains approximately 10 mg of boswellia extract.

CA 02559634 2006-09-13
-3-
White willow bark acts as a pain reliever in the composition. It is
preferably prepared from Salalix alba in a form standardized to 25%
salacin. One dosage of the composition contains approximately 50 mg of
white willow bark.
Yucca root powder acts as an anti-inflammatory agent in the
composition. It is derived from Yucca schidigera. One dosage of the
composition contains approximately 15 mg of yucca root powder.
Devil's claw acts as an anti-inflammatory agent in the composition.
It is derived from Harpagophytum procumbens. One dosage of the
composition contains approximately 15 mg of devil's claw.
Sarsaparilla acts as an anti-inflammatory agent in the composition.
It is derived from Smilax sp. One dosage of the composition contains
approximately 15 mg of sarsaparilla.
Feverfew leaf powder acts as a pain reliever in the composition. It
is derived from Tanacetum parthenium. One dosage of the composition
contains approximately 10 mg of feverfew leaf powder.
Bromelain acts as an anti-inflammatory agent in the composition.
One dosage of the composition contains approximately 5 mg.
The collagen used in the composition is preferably Type II collagen.
The unhydrolyzed form is preferred for ready absorption into the body
tissues. Collagen promotes the rebuilding of cartilage. One dosage of the
composition contains approximately 30 mg of collagen.

CA 02559634 2006-09-13
-4-
Pantothenic acid is a component of the composition and promotes
tissue formation. One dosage of the composition contains approximately 5
mg.
The preferred minerals in the composition are copper, manganese
and selenium. Copper helps produce red blood cells and connective tissue.
One dosage of the composition contains approximately 350 mcg of copper.
Manganese is a component that acts in the process of bone
metabolism. One dosage of the composition contains approximately 750
mcg of manganese.
Selenium is a non-metallic mineral component of the composition
that is a factor in the maintenance of health body cells and tissues. One
dosage of the composition contains approximately 13 mcg of selenium.
The composition of invention is made by the following method. A
mixture of the glucosamine sulphate, the collagen and the plant materials
or extracts, all of which are in dry powdered form, is prepared. A second
mixture is prepared comprising the pantothenic acid and the copper,
manganese and selenium. These two mixtures are mixed together and the
resulting powdered mixture is used to prepare single-dosage capsules.
Alternatively, the composition and/or the second mixture (the pantothenic
acid, copper, manganese and selenium) can be used by topical
administration.
Example 1
A pharmaceutical preparation is compounded as a dry powdered mix
and is made into single-dosage capsules. The ingredients, their weight

CA 02559634 2006-09-13
-5-
percent in the total composition and their weights in a single capsule are as
shown in Table 1.
Ingredient Weight Percent Weight in Single
Capsule
Pantothenic acid 0.907 5 mg
Copper 0.0635 350 mcg
Manganese 0.136 750 mcg
Selenium 0.0235 13 mcg
Glucosamine sulphate 68.0 375 mcg
Boswellia extract 10.9 60 mg
Collagen 0.0054 30 mg
White willow bark 9.07 50 mg
Yucca root powder 2.73 15 mg
Devil's claw 2.73 15 mg
Sarsaparilla 2.73 15 mg
Feverfew leaf powder 1.81 10 mg
Bromelain 0.907 5 mg
The capsules are administered to an adult human at a rate of 4 to 6
capsules per day until the arthritic symptoms are relieved. They are then
administered at a maintenance dosage of 2 to 4 capsules per day.
Although the invention has been described in terms of specific
embodiments, it is not intended that the invention be limited to those
embodiments. Various modifications of the invention will be apparent to
those skilled in the art. The scope of the invention is defined by the claims
that follow.

Representative Drawing

Sorry, the representative drawing for patent document number 2559634 was not found.

Administrative Status

2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.

Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee  and Payment History  should be consulted.

Event History

Description Date
Time Limit for Reversal Expired 2009-09-14
Application Not Reinstated by Deadline 2009-09-14
Deemed Abandoned - Failure to Respond to Maintenance Fee Notice 2008-09-15
Application Published (Open to Public Inspection) 2008-03-13
Inactive: Cover page published 2008-03-12
Inactive: IPC assigned 2007-01-25
Inactive: IPC assigned 2007-01-25
Inactive: IPC assigned 2007-01-25
Inactive: First IPC assigned 2007-01-25
Inactive: IPC assigned 2007-01-25
Inactive: IPC assigned 2007-01-25
Inactive: IPC assigned 2007-01-25
Inactive: IPC assigned 2007-01-25
Inactive: IPC assigned 2007-01-25
Inactive: IPC assigned 2007-01-25
Inactive: IPC assigned 2007-01-25
Inactive: IPC assigned 2007-01-25
Inactive: IPC assigned 2007-01-25
Inactive: IPC assigned 2007-01-25
Inactive: IPC assigned 2007-01-25
Application Received - Regular National 2006-10-13
Filing Requirements Determined Compliant 2006-10-13
Letter Sent 2006-10-13
Inactive: Filing certificate - No RFE (English) 2006-10-13

Abandonment History

Abandonment Date Reason Reinstatement Date
2008-09-15

Fee History

Fee Type Anniversary Year Due Date Paid Date
Application fee - standard 2006-09-13
Registration of a document 2006-09-13
Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
KENT PEDERSEN
Past Owners on Record
ASHLEY SHIPTON
REINHARDT HAUKENFRERS
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Abstract 2006-09-12 1 13
Description 2006-09-12 5 198
Claims 2006-09-12 2 40
Courtesy - Certificate of registration (related document(s)) 2006-10-12 1 105
Filing Certificate (English) 2006-10-12 1 159
Reminder of maintenance fee due 2008-05-13 1 114
Courtesy - Abandonment Letter (Maintenance Fee) 2008-11-09 1 175